The NCCN and ASCO guidelines are somewhat divergent on this point with the ASCO guidelines stating that “all patients with metastatic colorectal carcinoma who are candidates for anti-EGFR antibody therapy should have their tumor tested for KRAS mutations...” [9]. This evidence concerns the gene KRAS and neoplasm.